Spyre Therapeutics
SYRE
SYRE
119 hedge funds and large institutions have $1.51B invested in Spyre Therapeutics in 2024 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 43 increasing their positions, 24 reducing their positions, and 18 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
1.68% more ownership
Funds ownership: 99.22% → 100.89% (+1.7%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
53% less call options, than puts
Call options by funds: $18K | Put options by funds: $38K
Holders
119
Holding in Top 10
3
Calls
$18K
Puts
$38K
Top Buyers
| 1 | +$37.3M | |
| 2 | +$33.6M | |
| 3 | +$20.9M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$17.8M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$13.1M |
Top Sellers
| 1 | -$36.5M | |
| 2 | -$22.3M | |
| 3 | -$21.3M | |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$15.7M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
-$11M |